Display options
Cite
Katisko K, Cajanus A, Huber N, et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021;92(12):1305-1312doi: 10.1136/jnnp-2021-326487.
Katisko, K., Cajanus, A., Huber, N., Jääskeläinen, O., Kokkola, T., Kärkkäinen, V., Rostalski, H., Hartikainen, P., Koivisto, A. M., Hannonen, S., Lehtola, J. M., Korhonen, V. E., Helisalmi, S., Koivumaa-Honkanen, H., Herukka, S. K., Remes, A. M., Solje, E., & Haapasalo, A. (2021). GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. Journal of neurology, neurosurgery, and psychiatry, 92(12), 1305-1312. https://doi.org/10.1136/jnnp-2021-326487
Katisko, Kasper, et al. "GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance." Journal of neurology, neurosurgery, and psychiatry vol. 92,12 (2021): 1305-1312. doi: https://doi.org/10.1136/jnnp-2021-326487
Katisko K, Cajanus A, Huber N, Jääskeläinen O, Kokkola T, Kärkkäinen V, Rostalski H, Hartikainen P, Koivisto AM, Hannonen S, Lehtola JM, Korhonen VE, Helisalmi S, Koivumaa-Honkanen H, Herukka SK, Remes AM, Solje E, Haapasalo A. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312. doi: 10.1136/jnnp-2021-326487. Epub 2021 Jun 29. PMID: 34187866.
Copy Download .nbib Format: NLM
Share it on

J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1305-1312. doi: 10.1136/jnnp-2021-326487. Epub 2021 Jun 29.

GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance.

Journal of neurology, neurosurgery, and psychiatry

Kasper Katisko, Antti Cajanus, Nadine Huber, Olli Jääskeläinen, Tarja Kokkola, Virve Kärkkäinen, Hannah Rostalski, Paivi Hartikainen, Anne M Koivisto, Sanna Hannonen, Juha-Matti Lehtola, Ville E Korhonen, Seppo Helisalmi, Heli Koivumaa-Honkanen, Sanna-Kaisa Herukka, Anne M Remes, Eino Solje, Annakaisa Haapasalo

Affiliations

  1. Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.
  2. A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  3. Neuro center, Neurology, Kuopio University Hospital, Kuopio, Finland.
  4. Department of Internal Medicine and Rehabilitation, Geriatrics, Helsinki University Hospital, Helsinki, Finland.
  5. Department of Neurosciences, University of Helsinki, Helsinki, Finland.
  6. Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.
  7. Institute of Clinical Medicine, Psychiatry, University of Eastern Finland, Kuopio, Finland.
  8. Mental Health and Wellbeing Center, Kuopio University Hospital, Kuopio, Finland.
  9. Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland.
  10. Medical Research Center, Oulu University Hospital, Oulu, Finland.
  11. Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland [email protected].

PMID: 34187866 DOI: 10.1136/jnnp-2021-326487

Abstract

BACKGROUND: Frontotemporal lobar degeneration (FTLD) and primary psychiatric disorders (PPD) are characterised by overlapping clinical features but different aetiologies. Here, we assessed for the first time the potential of blood glial fibrillar acidic protein (GFAP), marker of astrogliosis, as a discriminative and prognostic tool in FTLD and PPD.

METHODS: The levels of GFAP in serum (sGFAP) of patients with FTLD (N=107) and PPD (N=44) and GFAP in whole blood samples (bGFAP) from FTLD (N=10), PPD (N=10) and healthy controls (N=18) were measured. We evaluated whether the sGFAP levels associate with

RESULTS: sGFAP and bGFAP levels were elevated in the FTLD group compared with the PPD or control groups. Receiver operating characteristic analysis indicated an excellent diagnostic performance between FTLD and PPD (the area under the curve (AUC)=0.820, 95% CI 0.745 to 0.896). sGFAP and bGFAP levels showed a strong correlation and elevated sGFAP levels significantly associated with atrophy rate in the temporal cortex and predicted shorter survival time in patients with FTLD. No association with

CONCLUSIONS: sGFAP enabled differentiation of patients with FTLD and PPD and associated with shorter survival and more severe brain atrophy rate in patients with FTLD. These results suggest that blood-based GFAP represents a minimally invasive and useful biomarker in the differential diagnostics between patients with FTLD and PPD and in evaluating disease progression and astrogliosis in FTLD.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords: MRI; frontotemporal dementia

Conflict of interest statement

Competing interests: None declared.

Publication Types